The Lynx Group

NCCN 2014 Conference

Hollywood, FL—The updated National Comprehensive Cancer Network (NCCN) guidelines for the management of melanoma now include the BRAF inhibitor dabrafenib (Tafinlar) as a Category 1 recommendation for the primary treatment of patients with metastatic melanoma and BRAF mutation, as well as the use of the mitogen-activated protein kinase (MEK) inhibitor trametinib (Mekinist) for the treatment of patients with melanoma and BRAF mutation. These 2 drugs, which received US Food and Drug Administration (FDA) approval last year, are now added to the NCCN targeted therapies for the treatment of patients with advanced or metastatic melanoma.
Read Article

Hollywood, FL—The updated guidelines from the National Comprehensive Cancer Network (NCCN) for the management of non-Hodgkin lymphoma (NHL) includes new strategies in the management of diffuse large B-cell lymphoma (DLBCL) and new guidelines for T-cell lymphoproliferative disorders.
Read Article

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: